Inclusion Criteria for Colorectal Cancer Liver Metastasis Patients in Clinical Trial

Patients with colon cancer liver metastasis confirmed by organization or cellular pathology;// 2. Patients who have previously received first-line chemotherapy and have achieved disease control (PR+SD) evaluated by RECIST 1.1;// 3. Patients with colorectal cancer liver metastasis who have undergone curative local treatment (surgery, ablation, SBRT) and achieved no evidence of disease (NED). Definition of NED: a. After local treatment, no residual tumor or tumor activity is found in the primary and metastatic lesions using CT, MRI, PET-CT. b. No cancer cells are found in the biopsy of suspicious lesions.// 4. Patients who have completed NED and have no disease progression after adjuvant chemotherapy (such as 4-8 cycles of Xelox regimen, 6-12 cycles of FOLFOX regimen, or completion of fluoropyrimidine monotherapy and no longer receiving adjuvant chemotherapy recently);// 5. The time from the last chemotherapy to enrollment does not exceed 2 months;// 6. Performance status (ECOG) score ≤ 2;// 7. Age 18-75 years old (including 18 and 75 years old);// 8. Hematology: WBC> 3 × 109 /L; PLT> 80 × 109 /L; Hb> 90g/L;/ 9. Liver function: ALT and AST ≤ 2.5 × ULN; bilirubin ≤ 1.5 × ULN// 10. Renal function: serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CCr) ≥ 60ml/min;/ 11. Signed informed consent form, patients willing to undergo this treatment regimen, able to adhere to medication and have good compliance.